Cardiovascular events and intensity of treatment in polycythemia vera

Valerio De Stefano, Roberto Marchioli, Guido Finazzi, Giorgina Specchia, Rossella Cacciola, Riccardo Cavazzina, Daniela Cilloni, Elena Elli, Alessandra Iurlo, Roberto Latagliata, Francesca Lunghi, Monia Lunghi, Rosa Maria Marfisi, Pellegrino Musto, Arianna Masciulli, Caterina Musolino, Nicola Cascavilla, Giovanni Quarta, Maria Luigia Randi, Davide RapezziMarco Ruggeri, Elisa Rumi, Anna Rita Scortechini, Simone Santini, Marco Scarano, Sergio Siragusa, Antonio Spadea, Alessia Tieghi, Emanuele Angelucci, Giuseppe Visani, Alessandro Maria Vannucchi, Tiziano Barbui

Research output: Contribution to journalArticle

402 Citations (SciVal)

Abstract

Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial.
Original languageEnglish
Pages (from-to)22-33
Number of pages12
JournalNew England Journal of Medicine
Volume368
DOIs
Publication statusPublished - 2013

Keywords

  • Aged
  • Antineoplastic Agents
  • Cardiovascular Diseases
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Hematocrit
  • Humans
  • Hydroxyurea
  • Janus Kinase 2
  • Male
  • Middle Aged
  • Phlebotomy
  • Polycythemia Vera
  • Thrombosis

Fingerprint

Dive into the research topics of 'Cardiovascular events and intensity of treatment in polycythemia vera'. Together they form a unique fingerprint.

Cite this